Treatment By Disease Type

The following is a summary of the diseases treated with stem cell transplantation at Cancer Treatment Centers of America. Our Oncology Information Specialists are available 24 hours a day, 7 days a week if you wish to discuss the treatment options for a particular disease in more detail.

Acute Lymphocytic Leukemia

• Patients with relapsed ALL or with high risk disease in first remission are offered an allogeneic transplant using a matched related donor
• Selected patients in complete remission are offered an autologous transplant

Acute Myeloid Leukemia

• Patients with poor risk AML are offered an allogeneic stem cell transplant in first remission if they have a matched sibling donor
• Relapsed or refractory patients are offered an allogeneic stem cell transplant using a matched sibling
• Patients without an allogeneic donor are offered an autologous transplant in first remission if they have poor risk disease or in second remission
• Patients who are older than 60 years are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”

Aplastic Anemia

• Allogeneic transplantation from a matched sibling donor is offered to untreated patients or those who have failed ATG treatment.

Amyloidosis

• Patients with amyloidosis are offered high dose melphalan conditioning and autologous stem cell transplant

Chronic Lymphocytic Leukemia

• Patients with advanced/fludarabine-refractory/relapsed CLL are candidates for reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”

Chronic Myeloid Leukemia

• Allogeneic transplantation from a matched sibling donor is offered to patients in chronic or accelerated phase
• Patients who are older than 60 years are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”

Germ Cell Tumors

• Patients with recurrent or refractory germ cell tumors are offered high dose chemotherapy and autologous stem cell transplant

Hodgkin's Disease

• Relapsed or refractory Hodgkin's disease patients are offered high dose chemotherapy and autologous stem cell transplant
• Selective patients with relapsed or refractory Hodgkin's disease are offered allogeneic transplantation from a matched sibling donor
• Selected patients with relapsed Hodgkin’s disease who are older than 50 years are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”
• Selected patients with relapsed or refractory Hodgkin's disease are also offered an autologous stem cell transplant followed by a reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “tandem transplant”

Multiple Myeloma

• Patients with standard risk multiple myeloma up to the age of 70 years are offered a melphalan based conditioning regimen and autologous stem cell transplant
• Selected patients with high risk multiple myeloma are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant
• Selected patients with high risk multiple myeloma are also offered an autologous blood stem cell transplant followed by a reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “tandem transplant”

Myelodysplastic Syndrome

• Patients with high or high-intermediate risk myelodysplastic syndrome are offered targeted busulfan based conditioning regimen and allogeneic transplantation from a matched sibling donor
• Selected patients with high or high-intermediate risk myelodysplastic syndrome who are older than 60 years are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”

Myelofibrosis

• Selected patients with myelofibrosis are offered allogeneic transplantation from a matched sibling donor

Non-Hodgkin's Lymphoma

• Relapsed non-Hodgkin's disease patients are offered high dose chemotherapy and autologous stem cell transplant
• Selected patients with relapsed or refractory non-Hodgkin's disease are offered allogeneic transplantation from a matched sibling donor
• Selected patients with relapsed non-Hodgkin’s disease who are older than 50 years are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”
• Selected patients with relapsed or refractory non-Hodgkin's disease are also offered an autologous stem cell transplant followed by a reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “tandem transplant”

Renal Cell Carcinoma

• Patients with metastatic renal cell carcinoma are offered reduced intensity conditioning and allogeneic stem cell transplant using a matched sibling “mini transplant”

The best way to fully determine your eligibility for a stem cell transplant is to meet with one of our oncologists.